Primmune Therapeutics Hits Phase 2 Enrollment Milestone in Melanoma Study
Primmune Therapeutics enrolled its second patient in the INFLECTION-003 trial, unlocking a new financing tranche for its melanoma drug candidate.
San Diego-based Primmune Therapeutics announced Thursday that it has enrolled the second patient in its Phase 2 INFLECTION-003 clinical study, a milestone that triggered the release of a second tranche of financing to support continued development of its lead drug candidate.
The drug at the center of the trial, Polvitolimod HCl — also known as PRTX007 — is being evaluated as a potential curative therapy for patients with stage III melanoma in both neoadjuvant and adjuvant treatment settings. Neoadjuvant therapy is administered before primary surgery, while adjuvant therapy follows surgical intervention, together representing a comprehensive treatment window the company is targeting.
Read more HouseCanary Wins Court Approval for Chapter 11 Reorganization Financing →
Primmune describes itself as a biotech firm focused on harnessing both the innate and adaptive immune systems, positioning Polvitolimod HCl within a broader class of immunotherapeutic approaches that have drawn significant industry attention in oncology. The enrollment milestone and corresponding financing release signal the company is advancing through an early but critical phase of clinical validation.
Stage III melanoma represents a particularly challenging patient population, as the cancer has spread to nearby lymph nodes but not yet to distant organs, making the neoadjuvant and adjuvant window a strategic point for intervention. Clinical outcomes data from the INFLECTION-003 study could clarify whether Polvitolimod HCl offers meaningful benefit at this disease stage.
Continue reading at GlobeNewswire - Industry News on Financial Services.
